Bildkälla: Stockfoto

Egetis Therapeutics Q1: Good Progress for Flagship Project - Redeye

Redeye views the update regarding the Emcitate project as encouraging and, as the principal, positive take-away from the Q1’21 report.

Redeye views the update regarding the Emcitate project as encouraging and, as the principal, positive take-away from the Q1’21 report.
Börsvärldens nyhetsbrev
ANNONSER